News from shire plc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 11, 2015, 08:00 ET

Shire to Present New Research at American Psychiatric Association Annual Meeting

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that new research highlighting its commitment to the treatment and management of psychiatric...

May 06, 2015, 10:26 ET

Shire to Participate at the Deutsche Bank 40th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it will be participating in the Deutsche Bank 40th Annual Healthcare Conference in Boston, MA on...

May 04, 2015, 07:00 ET

Shire and Foundation Fighting Blindness Announce New Research Agreement

Shire plc (LSE: SHP, NASDAQ: SHPG) and the Foundation Fighting Blindness today announced a new agreement focused on furthering research for a...

Apr 30, 2015, 07:01 ET

Jeff Poulton Appointed Shire Chief Financial Officer and Joins Board of Directors

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the appointment of Jeff Poulton as Chief Financial Officer (CFO) and member of the Executive...

Apr 30, 2015, 07:00 ET

Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS

- Continued Advancement Toward Goal of Becoming a Leading Global Biotechnology Company Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited...

Apr 09, 2015, 13:55 ET

U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has accepted for filing the New Drug...

Apr 09, 2015, 02:00 ET

Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with Alagille Syndrome

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the 13-week Phase 2 IMAGO trial of its investigational compound SHP625 (LUM001) did not...

Apr 07, 2015, 02:00 ET

Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD

- Potential Launch of SHP465 Anticipated in Second Half of 2017  - Exclusivity for Shire's Overall ADHD Product Portfolio Extends...

Apr 06, 2015, 08:00 ET

Shire Comments on USPTO Petitions Related to LIALDA and GATTEX

Shire plc (LSE: SHP, NASDAQ: SHPG) acknowledges the two petitions filed with the U.S. Patent and Trademark Office (USPTO) on April 2nd by Hayman...

Apr 01, 2015, 07:00 ET

Natpara® (Parathyroid Hormone) for Injection Now Available in the U.S.

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Natpara® (parathyroid hormone) for injection is now available in the United States....

Mar 26, 2015, 08:00 ET

Shire and Cincinnati Children's Establish Rare Disease Research Collaboration

Shire plc (LSE: SHP, NASDAQ: SHPG) and Cincinnati Children's Hospital Medical Center today announced a three-year, broad research collaboration...

Mar 02, 2015, 07:00 ET

Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the company has submitted a New Drug Application (NDA) with the U. S. Food and Drug...

Feb 25, 2015, 09:00 ET

Shire to Present at the Cowen 35th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Flemming Ornskov, MD, Chief Executive Officer, will present at the Cowen 35th Annual...

Feb 24, 2015, 07:00 ET

Shire Acquires Meritage Pharma

Shire plc (LSE: SHP, NASDAQ: SHPG) and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an...

Feb 23, 2015, 01:00 ET

Shire Calls for Improved Rare Disease Diagnosis on Rare Disease Day 2015

- New awareness materials posted on Shire.com highlight the challenging diagnosis journey many people with a rare disease face  -...

Feb 21, 2015, 10:26 ET

Shire Completes Acquisition of NPS Pharma

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS...

Feb 12, 2015, 07:00 ET

Shire Delivers Record Revenues and Non GAAP Earnings per ADS in 2014, and Enters 2015 With Strongest-Ever Pipeline

Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the year to December 31, 2014. Full Year Financial Highlights...

Feb 02, 2015, 12:46 ET

Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder

 Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) approved Vyvanse® (lisdexamfetamine...

Jan 30, 2015, 18:24 ET

Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) approved Vyvanse® (lisdexamfetamine...

Jan 27, 2015, 17:00 ET

U.S. Supreme Court Grants Shire Petition

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Supreme Court granted Shire's petition in the Shire v. Watson patent case...